• 1
    Nerurkar VR, Chitale AR, Jalnapurkar BV, Naik SN and Lalitha VS. Comparative pathology of canine mammary tumours. Journal of Comparative Pathology 1989; 101: 389397.
  • 2
    Rutteman GR, Withrow SJ and MacEwen EG. Tumors of the mammary gland. In: Small Animal Clinical Oncology. SJ Withrow and DR MacEwen Eds., Philadelphia, WB Saunders Company, 2001: 455477.
  • 3
    Misdorp W and Hart AA. Prognostic factors in canine mammary cancer. Journal of the National Cancer Institute 1976; 56: 779786.
  • 4
    Zaidan Dagli ML. The search for suitable prognostic markers for canine mammary tumors: A promising outlook. Veterinary Journal 2008; 177: 35.
  • 5
    De Matos AJ, Lopes CC, Faustino AM, Carvalheira JG, Dos Santos MS, Rutteman GR and Gartner Mde F. MIB-1 labelling indices according to clinico-pathological variables in canine mammary tumours: a multivariate study. Anticancer Research 2006; 26: 18211826.
  • 6
    de las Mulas JM, Millán Y and Dios R. A prospective analysis of immunohistochemically determined estrogen receptor α and progesterone receptor expression and host and tumor factors as predictors of disease-free period in mammary tumors of the dog. Veterinary Pathology Online 2005; 42: 200212.
  • 7
    Lee CH, Kim WH, Lim JH, Kang MS, Kim DY and Kweon OK. Mutation and overexpression of p53 as a prognostic factor in canine mammary tumors. Journal of Veterinary Science 2004; 5: 6369.
  • 8
    Martin de las Mulas J, Ordas J, Millan Y, Fernandez-Soria V and Ramon y Cajal S. Oncogene HER-2 in canine mammary gland carcinomas: an immunohistochemical and chromogenic in situ hybridization study. Breast Cancer Research and Treatment 2003; 80: 363367.
  • 9
    De Matos AJ, Lopes CC, Faustino AM, Carvalheira JG, Rutteman GR and Gartner Mde F. E-cadherin, beta-catenin, invasion and lymph node metastases in canine malignant mammary tumours. APMIS 2007; 115: 327334.
  • 10
    Gama A, Paredes J, Gartner F, Alves A and Schmitt F. Expression of E-cadherin, P-cadherin and beta-catenin in canine malignant mammary tumours in relation to clinicopathological parameters, proliferation and survival. Veterinary Journal 2008; 177: 4553.
  • 11
    Coffer PJ and Burgering BM. Forkhead-box transcription factors and their role in the immune system. Nature Reviews Immunology 2004; 4: 889899.
  • 12
    Hori S, Nomura T and Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 10571061.
  • 13
    Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS and Linehan DC. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. Journal of Immunology 2002; 169: 27562761.
  • 14
    Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF and Korangy F. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Research 2005; 65: 24572464.
  • 15
    Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H and Fujii H. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clinical Cancer Research 2003; 9: 44044408.
  • 16
    Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L and Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Medicine 2004; 10: 942949.
  • 17
    Merlo A, Casalini P, Carcangiu ML, Malventano C, Triulzi T, Menard S, Tagliabue E and Balsari A. FOXP3 expression and overall survival in breast cancer. Journal of Clinical Oncology 2009; 27: 17461752.
  • 18
    Misdorp W, Else RW, Hellmen E and Lipscomb TP. Histological Classification of Mammary Tumors of the Dog and the Cat. Armed Forces Institute of Pathology, Washington, DC, 1999.
  • 19
    Biller BJ, Elmslie RE, Burnett RC, Avery AC and Dow SW. Use of FoxP3 expression to identify regulatory T cells in healthy dogs and dogs with cancer. Veterinary Immunology and Immunopathology 2007; 116: 6978.
  • 20
    Allred DC, Harvey JM, Berardo M and Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Modern Pathology 1998; 11: 155168.
  • 21
    Hsu CY, Ho DM, Yang CF, Lai CR, Yu IT and Chiang H. Interobserver reproducibility of Her-2/neu protein overexpression in invasive breast carcinoma using the DAKO HercepTest. American Journal of Clinical Pathology 2002; 118: 693698.
  • 22
    Gilbertson SR, Kurzman ID, Zachrau RE, Hurvitz AI and Black MM. Canine mammary epithelial neoplasms: biologic implications of morphologic characteristics assessed in 232 dogs. Veterinary Pathology 1983; 20: 127142.
  • 23
    Withrow SJ and Vail DM. Withrow & MacEwen's Small Animal Clinical Oncology, 4th edn. Saunders, 2007: 619636.
  • 24
    Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL and Banham AH. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. Journal of Clinical Oncology 2006; 24: 53735380.
  • 25
    Viguier M, Lemaitre F, Verola O, Cho MS, Gorochov G, Dubertret L, Bachelez H, Kourilsky P and Ferradini L. Foxp3 expressing CD4 +  CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. Journal of Immunology 2004; 173: 14441453.
  • 26
    Bohling SD and Allison KH. Immunosuppressive regulatory T cells are associated with aggressive breast cancer phenotypes: a potential therapeutic target. Modern Pathology 2008; 21: 15271532.
  • 27
    Sartin EA, Barnes S, Kwapien RP and Wolfe LG. Estrogen and progesterone receptor status of mammary carcinomas and correlation with clinical outcome in dogs. American Journal of Veterinary Research 1992; 53: 21962200.
  • 28
    Chang CC, Tsai MH, Liao JW, Chan JP, Wong ML and Chang SC. Evaluation of hormone receptor expression for use in predicting survival of female dogs with malignant mammary gland tumors. Journal of the American Veterinary Medical Association 2009; 235: 391396.
  • 29
    Rungsipipat A, Tateyama S, Yamaguchi R, Uchida K, Miyoshi N and Hayashi T. Immunohistochemical analysis of c-yes and c-erbB-2 oncogene products and p53 tumor suppressor protein in canine mammary tumors. Journal of Veterinary Medical Science 1999; 61: 2732.
  • 30
    Ahern TE, Bird RC, Bird AE and Wolfe LG. Expression of the oncogene c-erbB-2 in canine mammary cancers and tumor-derived cell lines. American Journal of Veterinary Research 1996; 57: 693696.